Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.
Himuro H, Nakahara Y, Igarashi Y, Kouro T, Higashijima N, Matsuo N, Murakami S, Wei F, Horaguchi S, Tsuji K, Mano Y, Saito H, Azuma K, Sasada T.
Himuro H, et al. Among authors: tsuji k.
Cancer Immunol Immunother. 2023 Aug;72(8):2829-2840. doi: 10.1007/s00262-023-03464-w. Epub 2023 May 16.
Cancer Immunol Immunother. 2023.
PMID: 37188764
Free PMC article.